News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Publication

Article

July 6, 2023

Pharmaceutical Executive

Pharmaceutical Executive: July 2023
Volume43
Issue 7

Shifting Macro Trends Offer Hope for Biotech Performance Boost

Author(s):

Barbara Ryan

But will Washington’s dealmaking stance upend the momentum?

Barabara Ryan

For the first time since January 2022, the Fed did not raise interest rates at its latest meeting, halting a streak of 10 straight previous hikes and putting at least a pause on the most rapid Fed-induced rise in interest rates in history. That is great news for rate-sensitive biotech stocks. The prolonged and unrelenting string of rate hikes was the No. 1 enemy of biotech valuations, which—as the longest dated of assets—trade inversely with rates. While the market is not wholly convinced that we have seen the last Fed rate hike, it does appear to be looking ahead to a potential for future rate cuts due to a slowdown in inflation, economic growth, rising unemployment, and (potentially) a recession.

This Fed pivot is a major positive shift in the macro climate in favor of biotech. Combined with continued solid momentum in M&A, it has fueled more than a 20% rally off the year-to-date lows as investors rotate back into growth from value. To be expected, capital markets activity has picked up with a healthy flow of follow-on offerings. According to data from SVB Securities, the largest participants, not surprisingly, are the biotech-dedicated investors who have been the biggest winners in M&A trades this year. If sector performance continues to be positive, other life sciences funds will seek out alpha here as will the long-departed generalist investors.

The number of companies in the sector trading below cash is also now declining with the valuation correction, positive datasets, and newfound discipline behind spending, program prioritization, and consolidation.

M&A tailwind remains a reason for optimism

Large pharma is flush with cash and—according to EY’s most recent annual Firepower report—they have more than $1.4 trillion to fund M&A, strategic partnerships, and collaborations. M&A has always been a core pillar of leading companies’ growth strategies, and emerging biotech innovators are their targets. The need has never been greater. In addition, they will face LOEs for products with revenues exceeding $300 billion, beginning in 2025. I expect a strong year of M&A and dealmaking in 2023.

My colleague, Tim Opler of Stifel, says of this year’s M&A activity: “It’s a ‘blistering’ pace on track for $300 billion by year’s end, which could approach an all-time deal record of $328 billion in 2019.” These metrics are according to his firm’s research.

While macro factors may be shifting from headwinds to tailwinds, there are industry-specific storm clouds overhead fueling uncertainty that could threaten short- and long-term fundamentals. Companies and investors will have to monitor these closely.

In a Financial Times article titled “Big Pharma Dealmaking Recovers with $85bn M&A Splurge,” Jamie Smyth talks about M&A trends and the potentially chilling effect of the Federal Trade Commission’s Amgen-Horizon Therapeutics merger suit on biopharmaceutical innovation. Smyth cites Paul Hastings, chief executive of Nkarta, an early-stage biotech company, and an outgoing chair of BIO, the biotech industries’ main lobbying group. Hastings warns “that US antitrust authorities’ tougher stance on pharma/biotech deals risks upending a decades-long business model that underpins innovation. This model attracts investors to biotechs that are pursuing high-risk research in the knowledge that large companies may later buy them and supply the funds needed to complete expensive clinical trials and [commercialize] new drugs.” Smyth also adds that, in the past two decades, small- to mid-sized biotechs have grown in importance to drug development.

The Inflation Reduction Act (IRA), passed in August of 2022, gave Medicare the power to lower prices on certain top-selling drugs that have no competition—starting with 10 medicines in 2026. But the details of the process were left to the US Department of Health and Human Services (HHS) to work out, and it has since released initial guidance and a timeline that will name the first set of drugs up for negotiation by Sept. 1. In addition, the US Chamber of Commerce, Merck, and Bristol Myers Squibb are suing HHS over the IRA, arguing that is unconstitutional.

I believe it’s true that fundamentals for many across our industry are strong, innovation is alive and well, and M&A is—and always has been—a core pillar of the growth strategies for the largest companies; and there is more money to fund it than ever. Biopharma has always been a growth industry, and I don’t believe that has changed or will. There is a lot of money earmarked to be invested behind good data, and patients will be the ultimate beneficiary of the substantive advances our industry continues to deliver.

Download Issue PDF
Articles in this issue

Pharm Exec roundtable
The AI Revolution Has Arrived: Shaping the Next Generation of Pharma Marketing
Kabir Nath
Crossing the Brain Barrier
Matthew Arnold
Biotech’s Survival Story: Companies Bear Down for Lean Years
Celeste Warren
DE&I in Pharma: A Shared Aim Promoting Inclusivity from Non-Leadership Roles
Doron Aspitz
Harnessing AI for Pharma Sales
Bruce Liu
Tapping New and Improved Drug Innovations in Asia

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Matthew Yelovich, Cleary Gottlieb, Theranos Case
Marcel Botha, 10XBeta
Related Content
Advertisement
Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million
August 22nd 2025

Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million

Don Tracy, Associate Editor
XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction
August 22nd 2025

XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction

Don Tracy, Associate Editor
Boehringer Ingelheim, AnGes Ink Deal to Produce Next-Generation PAD Gene Therapy
August 22nd 2025

Boehringer Ingelheim, AnGes Ink Deal to Produce Next-Generation PAD Gene Therapy

Don Tracy, Associate Editor
CSL to Layoff 15% of Employees, Close 22 US-based Plasma Centers
August 22nd 2025

CSL to Layoff 15% of Employees, Close 22 US-based Plasma Centers

Don Tracy, Associate Editor
Skyhawk Therapeutics, Merck KGaA Strike Multi-Billion Dollar Deal to Advance RNA Therapies in Neurology
August 22nd 2025

Skyhawk Therapeutics, Merck KGaA Strike Multi-Billion Dollar Deal to Advance RNA Therapies in Neurology

Don Tracy, Associate Editor
Navigating Divergent Currents: Biopharma Review and Outlook
August 22nd 2025

Navigating Divergent Currents: Biopharma Review and Outlook

Peter Young
Related Content
Advertisement
Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million
August 22nd 2025

Gilead Subsidiary Kite to Acquire Interius BioTherapeutics for $350 Million

Don Tracy, Associate Editor
XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction
August 22nd 2025

XOMA Royalty Subsidiary to Acquire Mural Oncology in Premium Cash Transaction

Don Tracy, Associate Editor
Boehringer Ingelheim, AnGes Ink Deal to Produce Next-Generation PAD Gene Therapy
August 22nd 2025

Boehringer Ingelheim, AnGes Ink Deal to Produce Next-Generation PAD Gene Therapy

Don Tracy, Associate Editor
CSL to Layoff 15% of Employees, Close 22 US-based Plasma Centers
August 22nd 2025

CSL to Layoff 15% of Employees, Close 22 US-based Plasma Centers

Don Tracy, Associate Editor
Skyhawk Therapeutics, Merck KGaA Strike Multi-Billion Dollar Deal to Advance RNA Therapies in Neurology
August 22nd 2025

Skyhawk Therapeutics, Merck KGaA Strike Multi-Billion Dollar Deal to Advance RNA Therapies in Neurology

Don Tracy, Associate Editor
Navigating Divergent Currents: Biopharma Review and Outlook
August 22nd 2025

Navigating Divergent Currents: Biopharma Review and Outlook

Peter Young
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.